Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany

Author:

Häcker Brit,Schönfeld Nicolas,Krieger David,Otto-Knapp Ralf,Hittel Norbert,Pflugmacher Patricia,Bauer Torsten

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. World Health Organization . Global tuberculosis report 2019. Geneva, World Health Organization, 2019.

2. Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

3. Recent evidence on delamanid use for rifampicin-resistant tuberculosis;Pontali;J Thorac Dis,2019

4. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial;von Groote-Bidlingmaier;Lancet Respir Med,2019

5. CLSI . Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard—Second Edition. CLSI document M24-A2. Wayne, PA, Clinical and Laboratory Standards Institute, 2011.

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3